We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

93 hedge funds and large institutions have $1.55B invested in Theravance Biopharma in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 10

71% more call options, than puts

Call options by funds: $1.69M | Put options by funds: $983K

48% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 21

43% more capital invested

Capital invested by funds: $1.08B → $1.55B (+$464M)

8% more funds holding

Funds holding: 86 → 93 (+7)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.16% less ownership

Funds ownership: 87.19% → 86.03% (-1.2%)

Holders
93
Holders Change
+7
Holders Change %
+8.14%
% of All Funds
2.13%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
31
Reduced
21
Closed
10
Calls
$1.69M
Puts
$983K
Net Calls
+$702K
Net Calls Change
-$968K

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$19.9M
2
WIM
Woodford Investment Management
United Kingdom
+$13.1M
3
CS
Candriam SCA
Luxembourg
+$6.94M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.44M
5
Millennium Management
Millennium Management
New York
+$2.41M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$26.8M
2
First Manhattan
First Manhattan
New York
-$16.9M
3
CAM
Cormorant Asset Management
Massachusetts
-$5.45M
4
BNP Paribas Asset Management
BNP Paribas Asset Management
France
-$5.4M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$3.85M +$434K +15,919 +16%
OWIM
27
Old West Investment Management
California
$3.63M +$4.36K +160 +0.1%
AA
28
ALPS Advisors
Colorado
$3.19M +$488K +17,906 +22%
RA
29
Royce & Associates
New York
$3.05M – – –
Swiss National Bank
30
Swiss National Bank
Switzerland
$2.46M – – –
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$2.14M -$654 -24 -0%
AllianceBernstein
32
AllianceBernstein
Tennessee
$2.08M +$49.1K +1,800 +3%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$2.03M -$139K -5,100 -8%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$1.67M +$408K +14,971 +41%
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$1.51M – – –
II
36
Ibex Investors
Colorado
$1.51M +$1.26M +46,101 New
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$1.42M – – –
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$1.21M -$74.9K -2,750 -7%
NSEDCP
39
NJ State Employees Deferred Compensation Plan
New Jersey
$1.11M – – –
CS
40
Credit Suisse
Switzerland
$1.1M -$425K -15,601 -32%
VEA
41
Virtus ETF Advisers
New York
$1.05M +$59.2K +2,171 +7%
Barclays
42
Barclays
United Kingdom
$1.03M +$773K +28,347 +903%
State Board of Administration of Florida Retirement System
43
State Board of Administration of Florida Retirement System
Florida
$934K – – –
AIG
44
American International Group
New York
$929K +$14K +513 +2%
ProShare Advisors
45
ProShare Advisors
Maryland
$905K -$26.8K -983 -3%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$902K -$106K -3,880 -12%
Invesco
47
Invesco
Georgia
$846K +$101K +3,700 +17%
BFM
48
Boothbay Fund Management
New York
$690K +$576K +21,132 New
Citadel Advisors
49
Citadel Advisors
Florida
$688K -$319K -11,715 -36%
EGM
50
Engineers Gate Manager
New York
$662K +$552K +20,262 New
1
2
3 4 5

TBPH Hedge Fund Activity: Q3 2018 in Review

93 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2018, worth a combined $1.55B — up 43% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new TBPH positions and 10 closed out — a net gain of 9 holders — while 31 added to existing stakes and 21 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $19.9M. The largest seller was Armistice Capital, exiting entirely with an estimated $26.8M sold.

  • 93 institutional investors held Theravance Biopharma (TBPH) as of Q3 2018, up from 86 in Q2 2018.
  • Funds reported $1.55B of Theravance Biopharma stock for Q3 2018, up 43% quarter-over-quarter.
  • 19 funds opened new Theravance Biopharma positions in Q3 2018 and 10 closed out, a net change of +9 holders.
  • The largest Theravance Biopharma buyer in Q3 2018 was Consonance Capital Management, an estimated $19.9M added.
  • The largest Theravance Biopharma seller in Q3 2018 was Armistice Capital, an estimated $26.8M sold.

Based on aggregated 13F filings for Q3 2018.